Literature DB >> 21341080

In Vitro Model of Hypoxically Induced Nonreplicating Persistence of Mycobacterium tuberculosis.

L G Wayne1.   

Abstract

Great progress has been made in the latter half of the twentieth century in the understanding of the immunology of tuberculosis and of strategies for chemotherapeutic management of this disease. Indeed, given the evidence that the dominant, and perhaps sole, ecologic niche of Mycobacterium tuberculosis is the infected human host, it seemed reasonable to hope that the disease could not only be controlled, but eradicated by the end of this century (1). These hopes are dashed by the periodic resurgence of tuberculosis in various populations. Undoubtedly socioeconomic factors have played a major role in the failure to eradicate this disease, but another, neglected, factor is the apparent ability of the tubercle bacillus to remain in a relatively quiescent state in the host, neither replicating and causing progression of disease, nor dying off and disappearing from the host's tissues, in spite of apparently adequate immune responses and aggressive chemotherapy.

Entities:  

Year:  2001        PMID: 21341080     DOI: 10.1385/1-59259-147-7:247

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  28 in total

1.  Examining the basis of isoniazid tolerance in nonreplicating Mycobacterium tuberculosis using transcriptional profiling.

Authors:  Griselda Tudó; Ken Laing; Denis A Mitchison; Philip D Butcher; Simon J Waddell
Journal:  Future Med Chem       Date:  2010-08       Impact factor: 3.808

2.  Lipidomic analyses of Mycobacterium tuberculosis based on accurate mass measurements and the novel "Mtb LipidDB".

Authors:  Mark J Sartain; Donald L Dick; Christopher D Rithner; Dean C Crick; John T Belisle
Journal:  J Lipid Res       Date:  2011-02-01       Impact factor: 5.922

3.  Activity of drug combinations against dormant Mycobacterium tuberculosis.

Authors:  Perla Filippini; Elisabetta Iona; Giovanni Piccaro; Pascale Peyron; Olivier Neyrolles; Lanfranco Fattorini
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

Review 4.  Hit and lead criteria in drug discovery for infectious diseases of the developing world.

Authors:  Kei Katsuno; Jeremy N Burrows; Ken Duncan; Rob Hooft van Huijsduijnen; Takushi Kaneko; Kiyoshi Kita; Charles E Mowbray; Dennis Schmatz; Peter Warner; B T Slingsby
Journal:  Nat Rev Drug Discov       Date:  2015-10-05       Impact factor: 84.694

5.  Metronidazole plus rifampin sterilizes long-term dormant Mycobacterium tuberculosis.

Authors:  Elisabetta Iona; Federico Giannoni; Manuela Pardini; Lara Brunori; Graziella Orefici; Lanfranco Fattorini
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

Review 6.  Modelling a Silent Epidemic: A Review of the In Vitro Models of Latent Tuberculosis.

Authors:  Savannah E R Gibson; James Harrison; Jonathan A G Cox
Journal:  Pathogens       Date:  2018-11-15

7.  Activities of drug combinations against Mycobacterium tuberculosis grown in aerobic and hypoxic acidic conditions.

Authors:  Giovanni Piccaro; Federico Giannoni; Perla Filippini; Alessandro Mustazzolu; Lanfranco Fattorini
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

8.  Validation of the essential ClpP protease in Mycobacterium tuberculosis as a novel drug target.

Authors:  Juliane Ollinger; Theresa O'Malley; Edward A Kesicki; Joshua Odingo; Tanya Parish
Journal:  J Bacteriol       Date:  2011-11-28       Impact factor: 3.490

9.  Mathematical Model of Oxygen Transport in Tuberculosis Granulomas.

Authors:  Meenal Datta; Laura E Via; Wei Chen; James W Baish; Lei Xu; Clifton E Barry; Rakesh K Jain
Journal:  Ann Biomed Eng       Date:  2015-08-08       Impact factor: 3.934

10.  Mycobacterium bovis BCG vaccine strains lack narK2 and narX induction and exhibit altered phenotypes during dormancy.

Authors:  Ryan W Honaker; Amanda Stewart; Stephanie Schittone; Angelo Izzo; Michèl R Klein; Martin I Voskuil
Journal:  Infect Immun       Date:  2008-03-24       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.